Prothena Corporation plc PRTA
8.16 USD -0.07 (-0.85%)
At closeNov 13, 2026, 4:15 PM EST
8.17 +0.01 +0.12%
After hours · Nov 13, 4:15 PM ET
8.01 Day range 8.31
7.73 52-week range 11.80
- YTD
- -14.55%
- 1 year
- -19.84%
News
investorplace.com Insider Buying Signals: 3 Healthcare Stocks to Watch Insider buying and share buybacks have put Prothena, Rapport Therapeutics and Azenta on the radar. See the catalysts and risks behind each stock.
zacks.com Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High? The consensus price target hints at a 120.2% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
defenseworld.net Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Target Price of $20.00 Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat.com…
benzinga.com CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results and raising its FY26 EPS guidance. Other gaining stocks include SLGB, HIHO, WNW, CHNR, RDGT, ULBI,…
benzinga.com UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/xslF345X06/primary_doc.xml
benzinga.com Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20 Citizens analyst Jason N. Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $19 to $20.
benzinga.com Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $(0.34) by 276.47 percent. This is a 153.57 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter…
benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $12 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $11 to $12.
benzinga.com Prothena Corp Q4 Earnings Assessment 
benzinga.com Prothena Corp Q4 EPS $(0.40) Beats $(0.54) Estimate, Sales $21.000K Miss $1.334M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.54) by 25.93 percent. This is a 62.96 percent increase over losses of…
benzinga.com Earnings Scheduled For February 19, 2026 
benzinga.com Exploring Prothena Corp's Earnings Expectations 
benzinga.com Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday 
benzinga.com Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19 Citizens analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $11 to $19.
benzinga.com Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a…
benzinga.com Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.- benzinga.com Prothena Presents Phase 2 Clinical Study Data For Coramitug For Treatment Of ATTR Amyloidosis With Cardiomyopathy American Heart Association's Circulation Journal Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the…
- benzinga.com HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $30 HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $20 to $30.
- benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $10 to $11.
benzinga.com Prothena Corp Q3 Adj. EPS $(0.68) Beats $(0.69) Estimate, Sales $2.415M Miss $6.639M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.69) by 1.02 percent. This is a 38.18 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $36 Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and raises the price target from $15 to $36.
- benzinga.com Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
- benzinga.com HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $20 HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $14 to $20.
- benzinga.com Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation…
benzinga.com Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $11 JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price target from $29 to $11.
benzinga.com FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
benzinga.com Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.- benzinga.com Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $15 Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target from $81 to $15.
- benzinga.com What 4 Analyst Ratings Have To Say About Prothena Corp
- benzinga.com Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
- benzinga.com Prothena Reports Phase 1 Results For PRX012 In Alzheimer's; Explores Partnerships To Advance PRX012 And TfR-Linked Preclinical Program As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibodyPhase 1 ASCENT clinical program…
- benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $10 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and lowers the price target from $18 to $10.
- benzinga.com 9 Analysts Assess Prothena Corp: What You Need To Know
- benzinga.com HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $14 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $14 price target.
- benzinga.com Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
- benzinga.com Prothena Corp Q2 Adj. EPS $(1.73) Misses $(1.27) Estimate, Sales $4.420M Miss $6.180M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(1.27) by 36.01 percent. This is a 241.8 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com A Glimpse of Prothena Corp's Earnings Potential
- benzinga.com 8 Analysts Assess Prothena Corp: What You Need To Know
- benzinga.com Prothena Cuts Workforce By ~63% To Streamline Operations And Reduce Costs; Revises FY25 Financial Guidance Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating costs to those necessary to…
- benzinga.com Prothena and Roche Move Parkinson's Drug to Phase III in Bid for First Disease-Modifying Treatment Prothena Corporation plc (NASDAQ:PRTA) today announced partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's…
- benzinga.com B of A Securities Downgrades Prothena Corp to Underperform, Lowers Price Target to $4 B of A Securities analyst Tazeen Ahmad downgrades Prothena Corp (NASDAQ:PRTA) from Neutral to Underperform and lowers the price target from $22 to $4.
benzinga.com Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session